# Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

> **NCT01323920** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 35 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01323920
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-02
- **Final completion:** 2013-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323920, "Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01323920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*